

**Kitex Garments Limited**

(CIN: L18101KL1992PLC006528)

Regd. Office: Building No. VI/496, Kizhakkambalam,

Vilangu P.O, Aluva, Ernakulam – 683561, Kerala

Phone: 91 484 2585000, Fax: 91 484 2680604

Email: [sect@kitexgarments.com](mailto:sect@kitexgarments.com)Website: [www.kitexgarments.com](http://www.kitexgarments.com)

Ref: KGL/SE/2024-25/SEP/06

September 12, 2024

To,

<b>BSE Limited</b> Department of Corporate Services (Listing) 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, P J Towers, Dalal Street, Fort Mumbai, Maharashtra – 400 001 <b>Scrip Code : 521248</b>	<b>National Stock Exchange of India Ltd</b> Listing Department, 'Exchange Plaza', 5 <sup>th</sup> Floor, Plot No.C/1, G Block, Bandra - Kurla Complex, Bandra (E), Mumbai, Maharashtra – 400 051. <b>Scrip Symbol : KITEX</b>
--	---

Dear Sir/ Madam,

**Sub :- Submission of Newspaper Notice in respect of transfer of equity shares of the Company to Investor Education and Protection Fund (IEPF)**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copies of the newspaper notice for the attention of shareholders of the Company in respect of transfer of equity shares of the Company to Investor Education and Protection Fund published in newspapers on September 12, 2024 in accordance with the requirements of Section 124(6) of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 as amended.

This is for your information. Kindly take the same on your records.

Thanking you,

Yours faithfully

For **Kitex Garments Limited**

**Dayana Joseph**

Company Secretary & Compliance Officer



QUICKLY.

TVS Capital Funds gets new Research Partner



**Chennai:** Private equity firm TVS Capital Funds (TCF) has appointed Chandrasekar V as Partner, Research. In his new role at TCF, he will focus on enhancing the firm's research capabilities, driving data-driven insights and supporting strategic decision-making processes across the firm's investing activities. **OUR BUREAU**

Strides Pharma gets nod for OneSource CDMO

**Mumbai:** Strides Pharma Science Ltd announced today that it has received approval from equity shareholders and secured creditors to create OneSource, India's first specialty pharma Contract Development and Manufacturing Organization. The approval is a crucial step towards establishing OneSource as an independent entity covering advanced sectors like biologics, complex injectables, and oral technologies. **OUR BUREAU**

# India to host 2,200 GCCs by 2030, generating 2.8 million jobs: Report

**GROWTH SPURT.** Between FY19 and FY24, over 400 GCCs and 1,100 new centres have been established in India

**Our Bureau**  
Bengaluru

India is on track to host 2,100-2,200 global capability centres (GCCs), creating 2.5-2.8 million jobs by 2030, according to a Zinnov-Nasscom India GCC Landscape report. Currently, the country has 1,700 GCCs employing 1.9 million professionals.

According to the five-year landscape report on the GCC ecosystem in India, by 2030, the country's GCC market is estimated to grow to \$99-105 billion. "These centres can transform into sandboxes for solutions tailored to diverse markets. They can unlock new growth by monetising 'India to India' services, leveraging local market insights, and expanding their domestic footprint," the report noted.

**GCC BOOM IN INDIA**

Between FY19 and FY24, over 400 GCCs and 1,100 new centres have been estab-



**TIERED SURGE.** More than 220 GCC units are housed across tier-II and tier-III cities, building critical mass

lished in India, bringing the total number to over 1,700. In FY24, GCCs in the country generated \$64.6 billion in export revenue. The average GCC talent has expanded by around 24 per cent since FY19 and is estimated at over 1.130 employees in FY24, the report said.

Over 90 per cent of these GCCs operate as multi-functional centres, supporting technology, operations, and product engineering. The report refers to India as the GCC Capital of the World,

with a large base of 17 per cent of GCCs. The Americas continue their dominance with over 1,000 GCC units. While initially, the growth of GCCs was driven by large enterprises, more mid-market enterprises and unicorns are also setting up centres in India, with around 40 global unicorns having an India GCC presence as of 2024.

More than 220 GCC units are housed in emerging locations across tier-II and tier-III cities, with Ahmedabad, Kochi, Thiruvananthapuram,

and Coimbatore building critical mass.

Sindhu Gangadharan, Chairperson at Nasscom, said, "GCCs have rapidly evolved from being operational hubs to becoming true engines of innovation and strategic growth. Their maturity in digital capabilities, engineering excellence, and advanced technology solutions is remarkable."

Gangadharan added that as GCCs move along the maturity curve, they are positioned to lead global agendas, secure critical managerial roles, and shape decision-making processes, setting the stage for India to become a global leader in digital transformation and sustainable business practices.

**EVOLUTION OF GCCs**

The report highlights that GCCs have moved up the maturity scale, with almost 53 per cent of GCCs in the portfolio and transformation hub stages. ER&D GCCs contributed \$36.4 billion in revenue

and grew 1.3 times faster than the overall GCC growth rate.

Over the past five years, global roles in India have expanded, with over 6,500 such positions. Nearly a quarter of global engineering roles are based in India, with industries like aerospace, defence, and semiconductors focusing on next-generation technologies.

Pari Natarajan, CEO of Zinnov, said, "India has undeniably become the GCC capital of the world. India's GCCs are driving high-value charters, where we are witnessing a shift towards portfolio and transformation hubs, with increasing product ownership from India. The new digital tech narrative, including GenAI, automation, and productivity charters, is largely driven through the Centers of Excellence model."

He stated that by 2030, 70 per cent of Fortune 500 companies may expand their presence to India.

## Engineers India eyes more orders from Middle East

**Our Bureau**  
New Delhi

Vartika Shukla, Chairman of the State-run Engineers India (EIL), stated on Wednesday that the engineering and project management consultancy (PMC) firm has nearly doubled its private sector business, leveraging its six decades of experience in India and abroad.

The leading project management consultancy (PMC) in the oil and gas sector has diversified its portfolio across infrastructure, crude oil storage, fertilizers, ports, LNG, coal gasification, defence, renewables and clean energy in the past few years, aiding the Navratna company to enhance revenue streams.

"In terms of order inflow, we were working at 10-12 per cent business inflow from private sector. Today, we have 20 per cent business. With the volume of work, the business inflow that we have is substantial in terms of absolute value."

"In FY21, from the private sector, we had an inflow of around ₹233 crore and in FY24, we had an inflow of

about ₹650 crore," Shukla told reporters.

As of March 31, 2024, EIL's order book stood at ₹7,823 crore. In the current fiscal year, the CPSU has already secured new business worth ₹4,681 crore.

As on August 31, its order book has expanded to around ₹11,350 crore.

**TAPPING OVERSEAS BIZ**  
The EIL chairman emphasised that the company is aggressively tapping business opportunities overseas.

It has secured ₹499 crore in new contracts and re-entered Algeria and Kuwait.

The company is bullish on business prospects with the UAE, which is increasingly patterning with India to enhance trade relations.

EIL's unit in the UAE is profitable and the company is "hopeful" to secure assignments, both small and big, from ADNOC, she added.

"We had ₹32 crore business inflow from Abu Dhabi in FY22 and last year (FY24) we had a business of ₹146 crore. This year (FY25), we already have an inflow of about ₹141 crore," Shukla said.

## Drugmakers' patient access programmes are promising but gaps remain

**PT Jyothi Datta**  
Mumbai

Do patient access programmes undertaken by major pharmaceutical companies meet the needs of patients they are meant for?

A report from the Amsterdam-based Access to Medicine Foundation (ATMF) has found that large drugmakers are making ambitious commitments but more needs to be done in getting products to those who need them.

With Covid-19 and mpox, for instance, it has been observed that a product available in one region is not available in another, said Jayasree K Iyer, Chief Executive with ATMF, adding that a lot more needs to be done in getting products to regions that bear the disease burden.

Patient assistance programmes need to be embedded in business operations to get more products to more countries or all products to all coun-



**LIMITED AVAILABILITY.** It has been observed that a product available in one region is not available in another

tries, Iyer told *businessline*. There is a mismatch between the commitments of companies and the regions where there is a disease burden, she added.

**HEALTHCARE ACCESS**

Calling for more "precise and actionable" goals for greater impact, the report said, "Despite comprising 80 per cent of the global population, people in low- and middle-income countries (LMICs) still face significant challenges in accessing essential healthcare products.

As demand for these products grows in underserved regions, the restricted availability—often due to production by only a few companies or single suppliers—becomes more pressing."

The companies examined by the non-profit foundation included Astellas, Eli Lilly, BMS, Roche, Pfizer, GSK, Bayer, Novartis, Novo Nordisk, Takeda, J&J, Sanofi, Merck, Gilead, Eisai, Boehringer Ingelheim, AstraZeneca, MSD, Daiichi Sankyo and AbbVie.

While the large drugmakers

sell in India as well, Iyer pointed to examples such as tuberculosis (TB) drugs and diabetes products.

The first illustrated a scenario where access to drugs was facilitated by partners, including the Government and donors investing resources, and getting companies to deliver. But with diabetes and cancer, she said, oligopolies are resulting in huge gaps in access to treatments. And with non-communicable diseases being a public health issue, more robust plans need to be in place to get these products to people, rather than depend on donors, she said.

The report said, "19 of the 20 companies assessed have reported using approaches to track the patients they reach with their essential medicines in LMICs (low and middle-income countries)... However, there is no consensus on how to calculate the number of patients reached, resulting in widely varying approaches across companies."

## DCGI suspends approval for Entod's yet-to-be launched eye drops

**Our Bureau**  
Mumbai

The Drugs Controller General of India (DCGI) has suspended approval for Entod Pharmaceuticals' yet-to-be launched eye drops, for reasons including unauthorised promotion and concern that the by-prescription product would be used like an over-the-counter drug.

The approval is for the manufacture and marketing of pilocarpine hydrochloride ophthalmic solution USP 1.25 per cent for treating presbyopia in adults, the DCGI order said.

Outlining the claims by the company, the regulator

said the product had not been approved for the claim that it was "designed to reduce the need for reading glasses".

On the drops being "a non-invasive option that can enhance near vision without the need of glasses", the DCGI said it had not approved such a claim.

The regulator said the product provided an advanced alternative that augments vision in 15 minutes.

It added that the company had not obtained approval from the Central Licensing Authority to make the above claims.

**ENTOD TO CHALLENGE**

Entod's PresVu eye drops had been slated for launch in

October, its representatives had told *businessline*.

Responding to the DCGI's order, Nikhil K Masurkar, Entod's Chief Executive, said in a statement that they had not made an "unethical or false presentation of facts" on their eye drops.

"All facts disclosed to the media were strictly on the basis of the recent DCGI approval for treatment of presbyopia in adults and the results of the phase 3 clinical trial conducted by us in India," he said, adding that they had "decided to challenge this suspension in the court of law to get justice."

The company intends to challenge the suspension, the note said.

## Clearstream, Infosys collaborate to digitise issuance of securities

**Our Bureau**  
Bengaluru

Infosys has announced its collaboration with Clearstream, the post-trade services arm of Deutsche Börse, an international exchange organisation and a provider of market infrastructure.

The collaboration supported the Generation 2 launch of Clearstream's D7 platform, a digital post-trade platform that enables market participants to issue securities digitally.

**DIGITISING BOURSES**

Dennis Gada, Executive Vice-President and global head of Banking & Financial services at Infosys said, "We are delighted to have collaborated with Clearstream, part of Deutsche Börse, on their digital transformation journey towards the D7 platform for the issuance of securities.

This integration has empowered them to enhance time-to-market, streamline operations, simplify their technology landscape, and effectively manage regulatory changes, all while fostering sustainable growth," adding that this transformation sets an example for future modernisation and digitisation of the securities and stock exchange industry.

Daniel Besse, the CTO of Clearstream, said, "The enhanced platform lays the foundation for future digitisation of financial markets as adapting to market changes can be done expeditiously."

## Invesco Mutual Fund

**Invesco Asset Management (India) Pvt. Ltd.**  
(CIN: U67190MH2005PTC153471), 2101-A, 21<sup>st</sup> Floor, A Wing, Marathon Futurex, N. M. Joshi Marg, Lower Parel, Mumbai - 400 013  
Telephone: +91 22 6731 0000, Fax: +91 22 2301 9422, Email: [mfservices@invesco.com](mailto:mfservices@invesco.com)  
[www.invescomutualfund.com](http://www.invescomutualfund.com)

**NOTICE**

NOTICE is hereby given that Invesco Trustee Pvt. Ltd., (the Trustee to Invesco Mutual Fund) has approved the declaration of Income Distribution cum Capital Withdrawal ('IDCW') in the following schemes, the particulars of which are as under:

Name of the Scheme	Plan(s) / Option(s)	Amount of IDCW (Rs. per unit)*	NAV as on September 10, 2024 (Rs. per unit)	Record Date
Invesco India Corporate Bond Fund, an open ended debt Scheme predominantly investing in AA+ and above rated corporate bonds. A relatively high interest rate risk and relatively low credit risk.	Quarterly IDCW Option	19.2006	1165.8413	
Invesco India Gilt Fund, an open ended debt scheme investing in government securities across maturity. A relatively high interest rate risk and relatively low credit risk.	Direct Plan - Quarterly IDCW Option	24.7096	1050.9114	
Invesco India Ultra Short Duration Fund, an open ended ultra-short term debt scheme investing in instruments such that the Macaulay duration <sup>^</sup> of the portfolio is between 3 months to 6 months. A relatively low interest rate risk and moderate credit risk.	Quarterly IDCW Option	18.0038	1079.7180	September 17, 2024 <sup>#</sup>
	Direct Plan - Quarterly IDCW Option	51.5275	1102.0862	
Invesco India Medium Duration Fund, an open ended medium term debt scheme investing in instruments such that the Macaulay duration <sup>^</sup> of the portfolio is between 3 years and 4 years. A relatively high interest rate risk and moderate credit risk.	Quarterly IDCW Option	22.2580	1053.6731	
	Direct Plan - Quarterly IDCW Option	24.3306	1066.7708	

<sup>^</sup>Please refer to the heading 'A. Asset Allocation' under Part 'II. Information about the Scheme' of Scheme Information Document where the concept of Macaulay duration has been explained.

\*Distribution of the above IDCW is subject to the availability of distributable surplus and may be lower to the extent of distributable surplus available on the record date. IDCW payable to the unit holder(s) will be lower to the extent of tax deducted at source, at applicable rates.

<sup>#</sup>or immediately following Business Day if that day is not a Business Day.

Face Value per unit is Rs. 1,000/-.

Pursuant to payment of IDCW, the NAV of the specified options of the aforesaid schemes would fall to the extent of payout and statutory levy, if any.

Unit holders of the aforesaid schemes, whose names appear in the records of the Registrar, KFin Technologies Limited, as at the close of business hours on **Tuesday, September 17, 2024** or immediately following Business Day (including valid purchase/switch-in application received till 3.00 p.m. on the record date, subject to the entire amount of subscription/ purchase as per the application / switch-in request is available for utilization by the scheme before the cut-off time on the record date) will be entitled to receive the IDCW.

Unit holders holding units in dematerialized (electronic) form whose names appear in the statement of beneficial owners maintained by the Depositories under the aforesaid schemes as at the close of business hours on **Tuesday, September 17, 2024** or immediately following Business Day will be entitled to receive the IDCW.

With regard to Unit holders under IDCW options of the aforesaid schemes, who have opted for IDCW Reinvestment facility, the IDCW due will be reinvested by allotting units for the IDCW amount (net of applicable taxes and stamp duty) (on the next Business Day after the Record Date) at a price based on the prevailing ex-IDCW NAV per unit on the record date.

**For Invesco Asset Management (India) Pvt. Ltd.**  
(Investment Manager for Invesco Mutual Fund)

**Sd/-**  
**Saurabh Nanavati**  
Chief Executive Officer

**Date: September 11, 2024**

**Mutual Fund investments are subject to market risks, read all scheme related documents carefully.**

**KITEX**  
**KITEX GARMENTS LIMITED**  
CIN: L18101KL1992PLC006528  
Regd office: Building No. V/496, Kizhakkambalam, Vilangu P O, Aluva, Kunnathunad - 683561, Kochi, Kerala  
Phone: 91 484 2585000, Fax: 91 484 2680604 Website: [www.kitexgarments.com](http://www.kitexgarments.com), E-mail: [sect@kitexgarments.com](mailto:sect@kitexgarments.com)

**NOTICE TO SHAREHOLDERS**  
[w.r.t. transfer of equity shares of the Company to Investor Education and Protection Fund (IEPF)]  
Shareholders are hereby informed that pursuant to Section 124(b) of the Companies Act, 2013, read with the Investor Education and Protection Fund (IEPF) Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("the Rules") as amended, the Interim dividend declared for the FY 2017-18, which remained unclaimed for a period of 7 years will be credited to the IEPF on December 09, 2024. The corresponding shares on which dividend was unclaimed for 7 consecutive years or more will also be transferred as per the procedure set out in the rules.  
The Company will not transfer such shares to the IEPF where there is a specific order of court/tribunal restraining any transfer of such shares or where the shares are hypothecated/pledged under the Depositories Act, 1996. In compliance to the rules, the Company has communicated individually to the concerned shareholder and the details of such shares liable to be transferred to IEPF are also made available on our website [www.kitexgarments.com](http://www.kitexgarments.com) under 'Investor Relations' section.  
The shareholders are requested to claim the interim dividend declared for the FY 2017-18 and onwards before the same is transferred to IEPF. The concerned shareholder(s), holding share(s) in physical form may please note that the shares are liable to be transferred to the IEPF account after issuing new share certificate or letter of confirmation for the purpose in favour of the IEPF Authority as per the rules and upon issue of such new share certificate letter of confirmation(s), the original share certificate(s) which stand registered in their name will be deemed to have been cancelled and non-negotiable. In case of shares held in demat form and liable to be transferred to IEPF, the Company shall inform the depository by way of corporate action for transfer to the demat account of the IEPF authority.  
Please note that no claim shall lie against the Company in respect of unclaimed dividend amount and shares transferred to IEPF. Shareholders may claim the dividend and corresponding shares transferred to IEPF including all benefits accruing on such shares, if any, from IEPF authorities after following procedure prescribed in the rules.  
In case the Company does not receive any communication from the concerned shareholder(s) by November 15, 2024, the Company shall transfer the unclaimed dividends to IEPF Account. The corresponding shares on which dividend is unclaimed for 7 consecutive years or more shall also be transferred without any further notice.  
In case of any query the concerned shareholder may contact the undersigned at its Registered Office address or Company's Registrar and Transfer Agent, i.e. Ms. Nirmla V. Assistant Manager, M/s. Cameo Corporate Services Limited at Subramanian Building No. 1, Club House Road, Chennai-600002, Telephone No. 044-4002741. E-mail: [investor@cameoindia.com](mailto:investor@cameoindia.com)

For Kitex Garments Limited  
Dayana Joseph  
Company Secretary

Kizhakkambalam  
September 11, 2024

Note: The shareholders are requested: (1) to register your correct address and email id with your depository participant concerned (2) update your complete bank account details with your depository participant for prompt direct credit of dividend entitlements (3) to approach us or IEPF, for any of your previous years unclaimed dividend entitlements.





പരീക്ഷാ അപേക്ഷ

തേജസ്വലം പത്താം ഞായറാഴ്ചയിൽ നടന്ന പരീക്ഷയുടെ ഫലം അറിയിക്കുക. ചേർന്ന പരീക്ഷാ കമ്മിറ്റി...



സ്വർണ്ണ ഗ്രാമിൻ ₹ 6715



പൊതുവാർത്തകൾ

ട്രംപിനെ പൊളിച്ചടുക്കി കമല

- ആദ്യ സംവാദത്തിൽ കാലിടറി ട്രംപ്
• കമല ജയിച്ചാൽ രണ്ട് വർഷത്തിനകം ഇസ്രായേൽ ഇല്ലാതാക്കുമെന്ന് ട്രംപ്
• ട്രംപിന്റെ നയങ്ങൾ അമേരിക്കയെ തകർക്കുമെന്ന് കമല
• സംവാദത്തിന് പിന്നാലെ ട്രംപ് മീഡിയ ഷെയററുകൾ ഇടിഞ്ഞു
• സംവാദത്തിൽ കമല ഹാരിസിന് മുൻതൂക്കമെന്ന് അമേരിക്കൻ മാധ്യമങ്ങൾ



സംവാദത്തിൽ കമലയും ട്രംപും പങ്കെടുത്തു. കമല ട്രംപിനെ പൊളിച്ചടുക്കി...

ട്രംപിന്റെ നയങ്ങൾ അമേരിക്കയെ തകർക്കുമെന്ന് കമല. ട്രംപിന്റെ നയങ്ങൾ...

സംവാദത്തിൽ കമല ഹാരിസിന് മുൻതൂക്കമെന്ന് അമേരിക്കൻ മാധ്യമങ്ങൾ. ഹാരിസിന് മുൻതൂക്കമെന്ന്...

വാഷിങ്ടൺ: യുഎസ് പ്രസിഡന്റ് തിരഞ്ഞെടുപ്പിനുള്ളിൽ മത്സരിക്കുന്നതിന് കമല ഹാരിസിന് മുൻതൂക്കമെന്ന് അമേരിക്കൻ മാധ്യമങ്ങൾ.

ട്രംപിന്റെ നയങ്ങൾ അമേരിക്കയെ തകർക്കുമെന്ന് കമല. ട്രംപിന്റെ നയങ്ങൾ...

സംവാദത്തിൽ കമലയും ട്രംപും പങ്കെടുത്തു. കമല ട്രംപിനെ പൊളിച്ചടുക്കി...

ട്രംപിന്റെ നയങ്ങൾ അമേരിക്കയെ തകർക്കുമെന്ന് കമല. ട്രംപിന്റെ നയങ്ങൾ...

സംവാദത്തിൽ കമല ഹാരിസിന് മുൻതൂക്കമെന്ന് അമേരിക്കൻ മാധ്യമങ്ങൾ.

ട്രംപിന്റെ നയങ്ങൾ അമേരിക്കയെ തകർക്കുമെന്ന് കമല. ട്രംപിന്റെ നയങ്ങൾ...

സംവാദത്തിൽ കമല ഹാരിസിന് മുൻതൂക്കമെന്ന് അമേരിക്കൻ മാധ്യമങ്ങൾ.

ട്രംപിന്റെ നയങ്ങൾ അമേരിക്കയെ തകർക്കുമെന്ന് കമല. ട്രംപിന്റെ നയങ്ങൾ...

Table with 2 columns: Item Name and Price. Includes items like 'കൊച്ചി', 'വെള്ളച്ചേട്ട', 'പഴുത്തുപുഴ', etc.

കേരള ജല അതോറിറ്റി. ഇലക്ട്രിക്കൽ ദർഘവസ് റേറ്റിംഗ്. Details about electricity rates and services.

Table with 2 columns: S.No and Amount. Details about the Fifty-Fifty Draw Result for KWA.

ക്ഷേമനുകൂല്യ നിഷേധത്തിനെതിരെ എസ്.ടി.യു പ്രതിഷേധ സമരങ്ങൾ നടത്തി

കോഴിക്കോട്: ഭരണമന്ത്രിയുടെ ക്ഷേമനുകൂല്യ നിഷേധത്തിനെതിരെ എസ്.ടി.യു പ്രതിഷേധ സമരങ്ങൾ നടത്തി.

ചരിത്രം കുറിച്ച പൊളാരിസ് ഡൗൺ

ന്യൂയോർക്ക്: മനുഷ്യനെ ബഹിരാകാശത്തുനിന്നു പുറംതള്ളിയ പൊളാരിസ് ഡൗൺ എന്ന ഹൃദയസ്തംഭന മരുന്നിനെക്കുറിച്ച ചരിത്രം.

ഫൈനെയ്റ്റ് എസ്റ്റേറ്റ് ഫിസിക്കൽ സഹകരണ സംഘം (ക്ലിപ്തം) നമ്പർ 226, പുളിയമ്പലം പി.ഒ, പുളിയമ്പലം ഫോൺ നമ്പർ: 828561006

Table with 4 columns: S.No, Name, Address, and Remarks. Details about the liquidation of the financial services cooperative.

Change of Name

Change of Name notice for I, FAMIYA, HOLDER OF INDIAN PASSPORT NO: K0379128.

Change of Name notice for SHIREEN YASIR ARAFATH.

Change of Name notice for SHON FRANCIS K.P.

Change of Name notice for SHAJAHAN NAZAR.

Change of Name notice for SHAJAHAN NAZAR (duplicate).

Change of Name notice for I, Nasirudeen Mohammed.

Change of Name notice for I, SHIJULA DUBAIR.

Change of Name notice for SHIREEN YASIR ARAFATH (duplicate).

Change of Name notice for SHON FRANCIS K.P. (duplicate).

Change of Name notice for SHAJAHAN NAZAR (duplicate).

Change of Name notice for SHAJAHAN NAZAR (duplicate).